#USA #New York #Securities Fraud #Pomerantz #RxSight

Pomerantz Law Firm Probes Possible Securities Fraud at RxSight, Inc.

The Pomerantz Law Firm, known for its commitment to investors, is currently investigating claims related to RxSight, Inc. (NASDAQ: RXST), which has garnered attention due to recent changes in its executive leadership. Investors with concerns regarding their investments in RxSight are encouraged to reach out to Danielle Peyton for further information.

The investigation centers around possible allegations of securities fraud and other illegal business practices by RxSight and some of its officers and directors. On December 22, 2025, the company issued a press release announcing the departure of its Chief Financial Officer, Shelley Thunen, who will remain until her successor is appointed or by January 31, 2026, whichever comes first. This unexpected change in the executive team raised eyebrows, particularly as it followed a management reshuffle disclosed earlier that month. Financial services firm BTIG expressed surprise at Thunen's exit, especially given early signs of operational improvements from RxSight.

The timing of these transitions signals potential ongoing challenges for the company's commercial trajectory. As a result of this announcement, RxSight’s stock experienced a significant decline, plummeting by $1.22 per share—or nearly 10%—to close at $11.01 the day after the news broke. The rapid response from the market indicates investor concerns over the stability and future direction of RxSight amid such managerial changes.

Pomerantz LLP, rooted in a legacy of fighting for the rights of investors, was established by Abraham L. Pomerantz, a pioneer in the field of securities class actions. With offices spanning New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, the firm has a notable track record of recovering substantial damages on behalf of class members victimized by securities fraud or corporate misconduct.

As the investigation unfolds, affected investors are urged to consider joining the potential class action against RxSight, as they may be entitled to compensation depending on the findings. Pomerantz continues to uphold the values of its founder, striving to secure justice for those caught in situations of corporate wrongdoing.

For those involved, this is a critical moment. If you have experienced financial losses as a result of RxSight’s recent performance and management decisions, connecting with Pomerantz could provide valuable insight and assistance moving forward. Investors can contact Danielle Peyton at Pomerantz LLP via email at [email protected] or by phone at 646-581-9980, extension 7980, to learn more about their options and the next steps in this ongoing case.